SCHEMBL6038659

SCHEMBL6038659

Cc1ccc(S(=O)(=O)Nc2nccnc2OCC2CCCO2)cc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.56
SLC12A2 P55011 1/20 0.52
SLC12A5 Q9H2X9 1/20 0.52
GAA P10253 2/20 0.49
RCE1 Q9Y256 1/20 0.48
POLB P06746 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
ALDH1A1 P00352 3/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
HSD17B10 Q99714 1/20 0.45
LMNA P02545 3/20 0.44
NPC1 O15118 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
RAB9A P51151 1/20 0.44
HTT P42858 2/20 0.44
TSHR P16473 1/20 0.43
CXCR4 P61073 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6039255 0.84 KDM4E (0.71) KDM4ESLC12A2SLC12A5GAARCE1
SCHEMBL6038670 0.83 EDNRA (0.57) GAAALDH1A1MEN1KMT2ALMNA
SCHEMBL6038831 0.82 EDNRA (0.56) KDM4EGAAALDH1A1MEN1KMT2A
SCHEMBL6038854 0.77 MEN1 (0.47) GAAALDH1A1MEN1KMT2ALMNA
SCHEMBL6039178 0.77 MEN1 (0.49) GAAALDH1A1MEN1KMT2ALMNA
SCHEMBL6038966 0.76 LMNA (0.47) KDM4EGAAALDH1A1MEN1KMT2A
SCHEMBL6038771 0.74 KDM4E (0.69) KDM4ENPSR1ALDH1A1MEN1KMT2A
SCHEMBL6038605 0.74 KMT2A (0.54) GAAPOLBALDH1A1MEN1KMT2A
SCHEMBL6038844 0.74 KMT2A (0.50) KDM4EGAAPOLBALDH1A1MEN1
SCHEMBL6038704 0.74 KDM4E (0.73) KDM4EALDH1A1MEN1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 KDM4E 3561/4885SLC12A2 1249/4885SLC12A5 1116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.